| P50 | author | Goce Spasovski | Q60452889 |
| | Francesco Locatelli | Q92104990 |
| P2093 | author name string | Christoph Wanner | |
| | Giuseppe Pontoriero | |
| | Frank Dellanna | |
| | Nada Dimkovic | |
| P2860 | cites work | Phosphate binders for preventing and treating bone disease in chronic kidney disease patients | Q24234036 |
| | Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO) | Q28236767 |
| | The emerging role of phosphate in vascular calcification | Q33595584 |
| | Association of HbA1c values with mortality and cardiovascular events in diabetic dialysis patients. The INVOR study and review of the literature | Q33916722 |
| | Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management | Q33939147 |
| | Joint association of hyperuricemia and reduced GFR on cardiovascular morbidity: a historical cohort study based on laboratory and claims data from a national insurance provider | Q33969455 |
| | ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). | Q34196167 |
| | Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines | Q34347054 |
| | The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial | Q34630074 |
| | Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study | Q34663424 |
| | Phosphorus binders and survival on hemodialysis | Q34907022 |
| | Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease | Q34939232 |
| | KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). | Q34994912 |
| | Serum amyloid A in uremic HDL promotes inflammation | Q35917487 |
| | Uric acid as a target of therapy in CKD. | Q36476464 |
| | Sevelamer hydrochloride: a review of its use for hyperphosphataemia in patients with end-stage renal disease on haemodialysis | Q37032561 |
| | Dyslipidemia in chronic kidney disease: an approach to pathogenesis and treatment | Q37210837 |
| | Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial. | Q53242888 |
| | Mortality in kidney disease patients treated with phosphate binders: a randomized study | Q57218797 |
| | Non-calcium-containing phosphate binders: comparing efficacy, safety, and other clinical effects | Q57219101 |
| | Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients | Q57221103 |
| | Pathogenesis of secondary hyperparathyroidism | Q71612728 |
| | Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis | Q73804043 |
| | Arterial stiffening and vascular calcifications in end-stage renal disease | Q73914339 |
| | Uric acid and cardiovascular risk | Q79689991 |
| | Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study | Q81376661 |
| | Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors | Q37231692 |
| | Risk factors for end-stage renal disease: 25-year follow-up | Q37307169 |
| | Effects of sevelamer and calcium-based phosphate binders on lipid and inflammatory markers in hemodialysis patients | Q37449096 |
| | Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status | Q37512120 |
| | Dyslipidemia, statins, and CKD patients' outcomes - review of the evidence in the post-sharp era. | Q38014005 |
| | KDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD). | Q39886186 |
| | Uric acid, CKD, and cardiovascular disease: confounders, culprits, and circles | Q42551663 |
| | Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk | Q42982775 |
| | Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperphosphataemia: a double-blind, randomized, placebo-controlled study | Q43279841 |
| | Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? | Q43890118 |
| | Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients | Q44039636 |
| | J-shaped mortality relationship for uric acid in CKD. | Q44985540 |
| | Evaluation of colestilan in chronic kidney disease dialysis patients with hyperphosphataemia and dyslipidaemia: a randomized, placebo-controlled, multiple fixed-dose trial | Q45026978 |
| | K/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease | Q45043772 |
| | Effect of MCI-196 (colestilan) as a phosphate binder on hyperphosphataemia in aemodialysis patients: a double-blind, placebo-controlled, short-term trial | Q45240235 |
| | Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients | Q46122319 |
| | Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis | Q46704866 |
| | Mineral metabolism, mortality, and morbidity in maintenance hemodialysis | Q50144395 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | placebo | Q269829 |
| P304 | page(s) | 1061-1073 | |
| P577 | publication date | 2013-12-02 | |
| P1433 | published in | Nephrology Dialysis Transplantation | Q15710302 |
| P1476 | title | The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study | |
| P478 | volume | 29 | |